Company Filing History:
1 out of 1,716 
1 out of 134 
1 out of 4 Years Active: 2007-2021
Title: Hiroshi Manya: Innovator in Glycan Therapeutics
Introduction
Hiroshi Manya, an accomplished inventor based in Tokyo, Japan, has made significant contributions to the field of glycan therapeutics. He holds two patents that address critical health issues related to abnormalities in dystroglycan sugar chain modification. Manya's innovative work has the potential to improve treatments for diseases associated with these modifications.
Latest Patents
Manya's latest patents include groundbreaking inventions that provide therapeutic solutions and testing methods for diseases linked with dystroglycan glycosylation abnormalities. The first patent offers a therapeutic agent that effectively acts on diseases related to abnormal glycosylation of dystroglycan, utilizing CDP-ribitol as the active ingredient. This discovery marks the first identification of CDP-ribitol as a sugar donor, essential for incorporating ribitol-phosphate into the dystroglycan glycan structure, aiming to restore the glycan of ISPD-deficient cells through supplementation therapy.
The second patent revolves around a novel enzyme with N-acetylglucosaminyltransferase (OMGnT) activity. This invention covers the enzyme, a polynucleotide encoding it, and methods for producing an enzyme protein with OMGnT activity. Manya's work in this realm enables the production of complex carbohydrates that traditional glycosyltransferases cannot synthesize, pushing the boundaries of carbohydrate chemistry.
Career Highlights
Hiroshi Manya has an impressive academic and professional background. He has worked at prestigious institutions such as the National Institute of Advanced Industrial Science and Technology and Kobe University. His research and inventions stem from his deep knowledge of glycan structures and the enzymes that modify them.
Collaborations
Throughout his career, Manya collaborated with notable coworkers, including Tamao Endo and Aruto Yoshida. Their collective expertise has contributed to the development of innovative therapeutic agents and testing methods, showcasing the impact of teamwork in advancing scientific frontiers.
Conclusion
Hiroshi Manya is a distinguished inventor whose patents reflect a commitment to addressing significant medical challenges through innovative glycan therapeutics. His work has the potential to revolutionize treatment options for diseases associated with dystroglycan modifications, demonstrating the importance of sustained research and collaboration in the field of biomedicine.